此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients

2014年7月3日 更新者:Mark Rosin、University of Saskatchewan

Blood is anticoagulated using a drug named heparin during open-heart surgery to allow it to safely pass through the heart-lung machine which pumps the blood throughout the body during the surgery. Each patient is given the heparin they need for their surgery. This means some patients receive more or less heparin than other patients. In this study, the investigators will be evaluating the current anticoagulation protocol for open heart surgery in use at the Royal University Hospital. The goal of this project is to compare patients who require and receive more heparin for proper anticoagulation to those patients who require and receive less heparin.

Open-heart surgery will proceed according to the standard hospital protocol. All research participants will be treated according to standard post-open heart surgery protocol in the ICU. This will include measurement of blood loss by keeping track of chest tube outputs and administration of blood transfusions.

This study focuses on Saskatoon Health Region patients having open heart surgery in terms of the protocol for anticoagulation and blood transfusions.

研究概览

地位

完全的

详细说明

This study examines heparin doses of patients having cardiopulmonary bypass supported surgery in terms of their sensitivity and resistance to heparin which is the standard anticoagulant used. The investigators use the Heparin Management System, an analyser that performs a heparin dose response test. In this test, a patient's whole blood is mixed with increasing amounts of heparin to determine the required dose to achieve a set level of anticoagulation. Patients who are found to resistant to heparin and needing a higher dose are thought by some to bleed more post operatively. It is my view that when the patient is given the correct amount of heparin which is then reversed by the correct amount of protamine (the reversal agent) the bleeding is not determined by heparin dose.

Hypothesis statement: Higher doses of heparin do not cause increased postoperative bleeding and transfusion events in the postoperative CPB patient.

Purposes of the Study

  1. Compare heparin sensitive and resistant patients in terms of postoperative bleeding and transfusion events.
  2. Determine the incidence of heparin sensitivity or resistance in patients.
  3. Identify preoperative factors that lead to heparin resistance or sensitivity in patients.
  4. Using the Heparin Dose Response test in determining heparin resistant and sensitive patients.
  5. Examination of anticoagulation protocol for open-heart surgery.
  6. Effect of preoperative antiplatelet and anticoagulant therapy on perioperative care.
  7. Use routine laboratory tests and values as well as common clinically available values in the conduct of the study so that results would be clinically relevant.

This is a prospective observational study. Patients will be divided into two groups dependant upon the results of their heparin dose response test; sensitive or resistant. Two groups of thirty will be selected to achieve 90% power at the 0.025 level of significance using a one-sided two-sample t-test.

The primary investigator will collect all data and submit the means to the statistician. Based on anecdotal experience the investigators expect there will be no difference between the two groups in terms of chest tube losses and transfusion events post-operatively.

This work is quite relevant to the investigators daily practice. Every open heart patient is anticoagulated with heparin and bleeds post operatively. The investigators goal is a reproducibly safe anticoagulation level and an acceptable level of chest tube losses. This translates to getting patients out of the operating room in a timely fashion and minimizing transfusion events.

研究类型

观察性的

注册 (实际的)

66

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Saskatchewan
      • Saskatoon、Saskatchewan、加拿大、S7N 0W8
        • Royal University Hospital
      • Saskatoon、Saskatchewan、加拿大、S7S 1E1
        • Royal University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 85年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

取样方法

非概率样本

研究人群

On the date of surgery, the patient would be brought to the operating room. The first blood sample would be drawn prior to heparinization. This would include analysis for Activated Clotting Time, Heparin Concentration/Heparin Dose Response, antithrombin and Thrombelastograph. During this first sampling interval, the patient's Heparin Sensitivity or Resistance is determined by Heparin Dose Response (slope). The following values would determine which one of the two study groups the patient would be assigned:

  • Sensitive to heparin: at or above 90 seconds/unit/millilitre
  • Resistant to heparin: below 89 seconds/unit/millilitre

描述

Inclusion Criteria:

  • Patients scheduled for elective or urgent CABG of two to six vessels.

Exclusion Criteria:

  • Preoperative:
  • Hemoglobin of less than 110grams/Litre
  • Under 18 years of age
  • Mass less than 75 kilograms
  • Presence of an intra-aortic balloon pump
  • Emergency surgery, requiring operative intervention within 24 hours of consultation to the cardiac surgery team
  • Need for cardiac surgical intervention in addition to planned CABG (with the exception of patent foramen ovale closure)
  • Ejection fraction of less than 50%, as determined by echocardiogram or angiography
  • Pulmonary hypertension with pulmonary artery pressures greater than 60mmHg
  • Presence of infectious endocarditis
  • Hepatic failure with impaired liver function, including INR greater than 1.5 Known diagnosed bleeding disorder
  • History of heparin induced thrombocytopenia and thrombosis
  • Renal failure with pre-operative creatinine greater than 200ml/min or oliguria with urine output less than 10millilitres/hour
  • Allergy to tranexamic acid
  • Pregnancy

Intraoperative:

  • Discovery of infectious endocarditis
  • Need for cardiac surgical intervention in addition to planned coronary CABG

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:队列
  • 时间观点:预期

队列和干预

团体/队列
Heparin Resistant
Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.
Heparin Sensitive
Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Chest Tube Losses
大体时间:Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs)
Chest tube losses will be measured in millilitres upon arrival in the Intensive Care unit (ICU) after six hours in the ICU and total chest tube losses during the ICU stay. Chest tube losses are the amount of blood collected in a graduated chest tube collection reservoir from chest tubes placed in the patient's chest wound at the end of surgery.
Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs)

次要结果测量

结果测量
措施说明
大体时间
Transfusion Events
大体时间:Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs)
Transfusion events to recorded will be the number of patients receiving units of red blood cells, units of platelets, units of plasma and units of cryoprecipitate.
Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mark W Rosin, MPS、Saskatoon Health Region

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年5月1日

初级完成 (实际的)

2013年1月1日

研究完成 (实际的)

2013年1月1日

研究注册日期

首次提交

2012年3月6日

首先提交符合 QC 标准的

2012年4月5日

首次发布 (估计)

2012年4月10日

研究记录更新

最后更新发布 (估计)

2014年7月8日

上次提交的符合 QC 标准的更新

2014年7月3日

最后验证

2014年7月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅